Business
Ardelyx Announces Presentations at ERA-EDTA Virtual Congress 2021
The OPTIMIZE Presentation Highlights Data Showing Tenapanor Allows a Greater Percentage of Previously Uncontrolled Patients to Achieve Targeted Serum
About this update from Ardelyx, Inc.
[{"type":"text","content":"The OPTIMIZE Presentation Highlights Data Showing Tenapanor Allows a Greater Percentage of Previously Uncontrolled Patients to Achieve Targeted Serum Phosphorus Levels\n The PHREEDOM Presentation Shows Positive Long Term Safety Data for Tenapanor Compared to Sevelamer\n\n\nFREMONT, Calif. and WALTHAM, June 7, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced two presentations highlighting new tenapanor data at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Virtual Congress 2021, taking place June 5-8, 2021. \n\n \n \n \n \n \n \n\n \nInterim data from the company's ongoing OPTIMIZE study shows that tenapanor can play a central role across the hyperphosphatemia treatment paradigm in adult patients with chronic kidney disease on dialysis, enabling greater achievement of phosphorus targets in binder-treated patients with phosphorus >5.5 and control of serum phosphorus in binder-naïve patients.\nIn a separate presentation, the company reported that patients who were on tenapanor had a smaller percentage of deaths and hospitalizations than those on the phosphate binder, sevelamer, in the long-term Phase 3 PHREEDOM study. \n\"Our OPTIMIZE study was designed to evaluate multiple methods for integrating the novel blocking mechanism of tenapanor into the hyperphosphatemia treatment paradigm with the goal of increasing the proportion of patients able to achieve target phosphorus levels,\" said David Rosenbaum, Ph.D. chief development officer. \"We are extremely pleased with the interim results demonstrating that tenapanor use resulted in approximately 50% of previously uncontrolled patients achieving target phosphorus levels when either switched to tenapanor monotherapy or with the addition of tenapanor with a concurrent reduction in binder dose. The interim results also demonstrated that two-thirds of binder-naïve patients who started on tenapanor monotherapy were able to achieve and/or maintain target phosphorus levels.\"\nDr. Steven Fishbane, Chief of Nephrology, Northwell Health and Professor of Medicine, Zucker School of Medicine, commented \"I am excited by these results that demonstrate both binder-treated and binder-naï...